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With Risk of Depression
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IMPORTANCE The role of large, rare copy number variants (CNVs) in neuropsychiatric
disorders is well established, but their association with common psychiatric disorders, such as
depression, remains unclear.
OBJECTIVE To examine the association of a group of 53 CNVs associated with
neurodevelopmental disorders and burden of rare CNVs with risk of depression.
DESIGN, SETTING, AND PARTICIPANTS This case-control study used data from the UK Biobank
study sample, which comprised 502 534 individuals living in the United Kingdom. Individuals
with autism spectrum disorder, intellectual disability, attention-deficit/hyperactivity disorder,
schizophrenia, or bipolar affective disorder diagnoses were excluded. Analyses were further
restricted to individuals of European genetic ancestry (n = 407074). The study was
conducted from January 2017 to September 2018.
EXPOSURES CNV carrier status.
MAIN OUTCOMES ANDMEASURES For the primary outcome, individuals who reported that
a physician had told them they had a depression diagnosis were defined as cases. Analyses
were repeated using 2 alternative depression definitions: self-reported lifetime depression
with current antidepressant prescription at the time of visit 1, and hospital discharge
diagnosis of depression.
RESULTS Copy number variants were identified in 488 366 individuals aged 37 to 73 years.
In total, 407074 individuals with European genetic ancestry (220 201 female [54.1%]; mean
[SD] age of 56.9 [8.0] years) were included in the study. Of these individuals, 23 979 (5.9%)
had self-reported lifetime depression and 383095 (94.1%) reported no lifetime depression.
The group of 53 neurodevelopmental CNVs was associated with self-reported depression
(odds ratio [OR], 1.34; 95% CI, 1.19-1.49, uncorrected P = 1.38 × 10−7), and these results were
consistent when using 2 alternative definitions of depression. This association was partially
explained by physical health, educational attainment, social deprivation, smoking status,
and alcohol consumption. A strong independent association remained between the
neurodevelopmental CNVs and depression in analyses that incorporated these other
measures (OR, 1.26; 95% CI, 1.11-1.43; P = 2.87 × 10−4). Eight individual CNVs were nominally
associated with risk of depression, and 3 of these 8 CNVs (1q21.1 duplication, Prader-Willi
syndrome duplication, and 16p11.2 duplication) survived Bonferroni correction for the
53 CNVs tested. After the exclusion of carriers of neurodevelopmental CNVs, no association
was found betweenmeasures of CNV burden and depression.
CONCLUSIONS AND RELEVANCE Neurodevelopmental CNVs appear to be associatedwith
depression, extending the spectrum of clinical phenotypes that are associated with CNV
carrier status.
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T heroleof large rarecopynumbervariants (CNVs) inneu-rodevelopmental disorders, including autism spec-trumdisorder, intellectual disability, attention-deficit/
hyperactivitydisorder,andschizophrenia, iswellestablished.1-5
In schizophrenia, associations have been reported with both
individualCNVsandan increasedburdenof raredeletions and
duplications.6-8 In contrast, theassociationbetweenCNVsand
risk of depression remainsunclear. Studies of CNVs indepres-
sionhave beenbasedon relatively small samples9-15 andhave
generated inconsistent results, and their findingshavenotmet
the criteria for genome-wide significance. TheUKBiobankda-
tabase now offers an opportunity to investigate the associa-
tion between CNVs and depression in a well-phenotyped
sample and on a larger scale than has been possible.
WereportaCNVanalysisofdepression in theentireUKBio-
bank sample. Previous studies have shown that a substantial
proportion of CNV enrichment in schizophrenia is explained
byCNVsassociatedwithneurodevelopmentaldisorders.6,16De-
pression shares a genetic risk with schizophrenia17,18 and is a
frequentcomorbiditywithneurodevelopmentaldisorders.19,20
Together, these findings suggest the hypothesis that, if CNVs
play a role indepression, neurodevelopmental CNVs are those
most likely to be associated.We also tested amore general hy-
pothesis that, at a genome-wide level, CNV burden is associ-
ated with depression.
Methods
This current study was conducted from January 2017 to Sep-
tember 2018, under the conditions of the UK Biobank project
number 14421. Ethical approval was granted to UK Biobank
by the North West Multi-Centre Ethics Committee, and all
participants provided informed consent to participate in UK
Biobank projects.
Sample
Between 2006 and 2010, the UK Biobank study recruited
502534 individuals (54% female) aged 37 to 73 years living in
the United Kingdom. Phenotypic data were collected at as-
sessment centers through touchscreendevices andnurse-led
interviews. Participants provided blood, urine, and saliva
samples.
Depression Phenotypes
Analyses of depression in the UK Biobank to date have used
multiple definitions of the disorder.21,22 In viewof this lack of
consensus on casedefinition,weused a relatively liberal defi-
nition of lifetime depression, rating as cases those individu-
alswho reported that a physicianhad told them theyhavede-
pression. We repeated our analyses using 2 alternative, more
conservative definitions of depression: (1) self-reported life-
time depression with current antidepressant prescription
at the time of visit 1 and (2) hospital discharge diagnosis of
depression.
For self-reporteddepressionwithantidepressantprescrip-
tionatvisit 1,weconstructedabinarydepressionvariableusing
the self-reported depression code 1286 in UK Biobank field
20002 and the antidepressant prescription codes in UK Bio-
bank field 20003. Individuals were included as cases (af-
fected status) if they reported that a physician had told them
theyhavedepression and that they received aprescription for
an antidepressantmedication at the time of first assessment.
Individuals who fulfilled only 1 of the 2 criteria (ie, self-
reporteddepressionorantidepressantprescriptionalone)were
excluded from analyses.
For hospital discharge diagnosis of depression, we in-
cluded individuals as affected if they had a hospital admis-
sionwithaprimaryor secondary International Statistical Clas-
sification of Diseases and Related Health Problems, Tenth
Revision (ICD-10), code fordepression (UKBiobankfields41202
and 41204) (Figure 1). For individuals assessed at Scottish as-
sessment centers, records fromgeneral hospitals but not psy-
chiatric hospitals were included (for assessment centers in
Wales andEngland, the records coveredbothgeneral andpsy-
chiatric hospitals). For these individuals, we accepted a sec-
ondary ICD-10 code for depression as evidence of depression
diagnosis as it could be coded during admission to a general
hospital. However, in the absence of primary ICD-10 codes for
depression, we were unable to determine the absence of de-
pression in controls (those with unaffected status). There-
fore, we removed Scottish controls from this variable.
In 2017, a total of 157 397 individuals completed an on-
line follow-upmental health questionnaire.We aimed to fur-
ther characterize the associations with depression pheno-
types in individualswhostatedon thisquestionnaire that they
hadever experiencedprolonged feelingsof sadnessordepres-
sion (UK Biobank field 20446). We examined data from the
following variables: (1) age at first episode of depression (UK
Biobank field20433), (2)durationofworstdepression (UKBio-
bank field 20438), and (3) lifetime number of depressed epi-
sodes (UK Biobank field 20442). The duration of worst de-
pressionwas coded in rangesofmonths (eg, less thanamonth,
between 1 month and 3 months). Previous data have shown
that themediandurationofadepressiveepisode is 3months.23
Therefore, this variable was dichotomized into 0 to 3months
and more than 3 months. The lifetime number of depressed
episodes was dichotomized using a median split approach
(median = 1).
Key Points
Question Are rare copy number variants associated with
depression in a large population sample?
Findings In this case-control study of 407074 individuals in the
UK Biobank study, neurodevelopmental disorder copy number
variants appear to be associated with the risk of depression in
those without neurodevelopmental disorders. Physical health,
educational attainment, social deprivation, smoking status, and
alcohol consumption are variables that partially explain this
association, and no evidence was found of an association between
measures of copy number variant burden and depression.
Meaning Neurodevelopmental copy number variants appear to
be associated with increases in the risk of depression in those
without neurodevelopmental disorders.
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Genotyping and CNV Calling
DNA was extracted from whole blood24 and then genotyped
(at theAffymetrixResearchServicesLaboratory)ontheUKBio-
bank Axiom and UK BiLEVE arrays. Genotypes were released
to Cardiff University after application to UK Biobank.We car-
ried out CNV calling with PennCNV-Affy 1.0.325 protocols
(PennCNV) using biallelic markers common to both genotyp-
ing platforms; this process is described in detail elsewhere
(eTable6 in theSupplement).26As reported inour group’spre-
vious CNV analyses in UK Biobank, no batch effects were
observed.27 The CNV burden analysis was carried out on the
CNV calls generated by PennCNV-Affy using the PLINK 1.07
analysis toolset (eTable 7 in the Supplement).28 Individual
samples were excluded if they had 30 or more CNVs, a wavi-
ness factor greater than 0.03 or less than –0.03, a single-
nucleotide polymorphism call rate lower than 96%, or log R
ratio SD higher than 0.35. Individual CNVs were excluded if
theywere coveredby fewer than20probes, hadadensity cov-
erage of less than 1 probe per 20000 base pairs, or a confi-
dence score lower than 10. eTable 9 in the Supplement pro-
vides the criteria for calling individual CNVs.
Defining CNV Sets and Statistical Analysis
Following the approach of our group’s recent study using UK
Biobank data,26 we defined a group of neurodevelopmental
CNVs as those 54 CNVs for which at least a nominally statisti-
cally significant evidence of association with neurodevelop-
mentaldisorders exists (P < .05; eTable 11 in theSupplement).3
We excluded the high-frequency 15q11.2 duplication, result-
ing in a final list of 53 neurodevelopmental CNVs. The level of
significancewas set atP < .05. In exploratory analyses,weex-
amined each of the CNVs with 5 or more observations for as-
sociationwith self-reported depression, and the results were
subjected to correction for 53 tests (P value threshold of
.00094).
The CNV burden analyses were carried out using PLINK
on regionsof variable copynumber at 3 size thresholds: (1) 100
kilobase (kb) or greater, (2) 500 kb or greater, and (3) 1 mega-
base (Mb) or greater. The CNVs were filtered for frequency at
less than 1%using the cnv-freq-exclude-above command, and
the overlapping lower copy repeat regions were filtered out
using the cnv-exclude command. PLINK outputs were con-
verted into CNV carrier status, which was used in regression
Figure 1. Flowchart of StudyMethods
3 Depression phenotypes
Self-reported depression
(29 231 with affected status; 
473 411 with unaffected status)
Self-reported depression with 
antidepressant prescription 
(18 714 with affected status; 
458 124 with unaffected status)
Hospital discharge diagnosis 
(14 369 with affected status; 
350 782 with unaffected status)
Exclusions
25 069
56 711
48 837
3135
From QC failure
From IBD
Without European genetic ancestry
With ASD/ID/ADHD/schizophrenia/BPAD
Self-reported depression 
(23 979 with affected status; 
383 095 with unaffected status)
Self-reported depression with 
antidepressant prescription 
(15 339 with affected status; 
370 876 with unaffected status)
Hospital discharge diagnosis 
(11 169 with affected status; 
284 179 with unaffected status)
Primary analysis
Association between 3 depression phenotypes
and phenotypic characterization variables 
(53 CNVs; rare CNV burden)
Mediation analysis
Association between depression and CNVs
(as explained by 5 variables: educational 
attainment, physical health, social deprivation,
smoking status, and alcohol consumption)
Exploratory analysis
Association between depression and 
individual CNV
Sex-specific analysis
ASD indicates autism spectrum
disorder; ADHD, attention-deficit/
hyperactivity disorder; BPAD, bipolar
affective disorder; CNV, copy number
variant; IBD, identity by descent;
ID, intellectual disability; QC, quality
control.
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analyses. For all burden analyses, carriers of the group of 53
CNVs associated with neurodevelopmental disorders were
excluded.
Association analyses were carried out in R (R Foundation
for Statistical Computing) using logistic or linear regression as
appropriate andwith age, sex, genotyping array, and the first
15 principal components as covariates (eTable 8 in theSupple-
ment).Analyseswere restricted to individuals ofEuropeange-
netic ancestry (n = 407074). This restrictionwas determined
by calculating aminimum covariance determinant estimator
of location and scatter, and then selecting individuals within
the 90th percentile of the minimum covariance determinant
distance (covMCD function in robustbase in R).29,30 We ex-
cluded individuals who had autism spectrum disorder, intel-
lectual disability, attention-deficit/hyperactivity disorder,
schizophrenia, orbipolar affectivedisorderdiagnosisbyaphy-
sician (UKBiobank fields 20002and20544) ordiagnosis code
during a hospital admission (UK Biobank fields 41202 and
41204).
Further Investigation of the Neurodevelopmental CNV
and Depression Association
Tobetter understand the association betweenneurodevelop-
mental CNVs anddepression,we investigatedwhether the as-
sociation was explained by variables known to be associated
withdepression31-34andpostulatedtobeassociatedwithCNVs:
(1) educational attainment (qualifications), (2) physical health
(affectedstatus for 1of themedicalphenotypesassociatedwith
these CNVs),27 (3) social deprivation (Townsend deprivation
index), (4) smoking (smokingstatus), and (5) alcohol consump-
tion (alcohol intake frequency).
Prior to this analysis, data from the academic qualifica-
tions fieldweredichotomizedand recoded into collegeoruni-
versity degree or all other qualifications, an approach previ-
ouslyused for this data field (UKBiobank field6138).35 For the
physical health variable,weusedaffected status for themedi-
cal phenotypesassociatedwith theCNVs ina recentwork from
our group.27 The social deprivation variable was measured
using theTownsenddeprivation indexcodes (UKBiobank field
189). Smoking was examined using smoking status (UK Bio-
bank field 20116), and alcohol consumption was examined
using alcohol intake frequency (UK Biobank field 1558).
Analyseswere carriedout using structural equationmod-
eling in the lavaanpackage inR,which generates estimates of
direct and indirect effects.36 Theproportionexplainedwases-
timated by indirect effect divided by total effect.
Sex-Specific Analyses
Previous studies have reported a small but significant excess
of large (≥500-kb) rare (frequency of <1%) CNVs in female
individuals.37 Recent evidence has also suggested that fe-
male children with anxiety or depression are more likely to
carry large CNVs than male children.38 This finding led us to
examine the rates of depression in female and male carriers
of CNVs in our sample. With the finding that an excess of fe-
male carriers have depression, we added to the main regres-
sionmodelan interactiontermconsistingof theproductofneu-
rodevelopmental CNVs and sex.
Results
We generated CNV calls for 488366 individuals aged 37 to 73
years. In total, 407074 individualswithEuropeangenetic an-
cestry (220201 female [54.1%]; mean [SD] age of 56.9 [8.0]
years)were included in the study.Of these individuals, 23979
(5.9%) had self-reported lifetime depression and 383 095
(94.1%) reported no lifetime depression (Figure 1).
Association Between CNVs and Depression
Thegroupof53neurodevelopmentalCNVswasassociatedwith
depression in theprimary analysis (odds ratio [OR], 1.34; 95%
CI, 1.19-1.49, uncorrected P = 1.38 × 10−7; Table). Of the indi-
viduals with depression, 363 (1.5%) carried at least 1 of the 53
neurodevelopmental CNVs comparedwith4368 (1.1%)of con-
trols. Analysis of the alternative depression phenotypes pro-
duced consistent results, with the effect size increasing with
more conservative definitions of depression (Table). The as-
Table. Association Analyses for Neurodevelopmental CNV and CNV BurdenWith 3 Depression Phenotypes in 407074 Individualsa
CNV Type Carrier, No. (%)
Self-reported Depression
(n = 23 979)
Self-reported Depression
With Antidepressant
Prescription on Visit 1
(n = 15 339)
Hospital Discharge Diagnosis
of Depression
(n = 11 169 )
OR (95% CI)
Uncorrected
P Value OR (95% CI)
Uncorrected
P Value OR (95% CI)
Uncorrected
P Value
Neurodevelopmental
CNVs
4731 (1.2) 1.34
(1.19-1.49)
1.38 × 10−7 1.42 (1.25-1.62) 1.18 × 10−7 1.51 (1.30-1.75) 2.95 × 10−8
Carrier status of rare
CNVsb
≥100 kb 197 779 (48.6) 1.01
(0.98-1.03)
.58 1.02 (0.98-1.05) .53 1.04 (1.00-1.08) .04
≥500 kb 35 351 (8.9) 1.05
(1.005-1.10)
.03 1.08 (1.02-1.14) .01 1.08 (1.01-1.15) .03
≥1 Mb 13 946 (3.4) 1.01
(0.94-1.08)
.80 1.02 (0.94-1.12) .59 1.04 (0.94-1.15) .41
Abbreviations: CNV, copy number variant; kb, kilobase; Mb, megabase;
OR, odds ratio.
a Analyses were restricted to those of European genetic ancestry (n = 407074)
and excluded individuals with CNV-associated neurodevelopmental or
neuropsychiatric disorders. Carriers of the group of 53 neurodevelopmental
CNVs were excluded from CNV burden analyses.
b Frequency less than 1%.
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sociation between the neurodevelopmental CNVs and self-
reporteddepression remainedafter removingcaseswithahos-
pital dischargediagnosis of depression (OR, 1.35; 95%CI, 1.21-
1.51; uncorrected P = 5.48 × 10−8). Restricting these analyses
to the subset of 12 schizophrenia-associated CNVs generated
similar results.5,6
After theexclusionof carriersof the53neurodevelopmen-
tal CNVs, aweak associationwas found between CNVs of 500
kb or greater and depression, which did not survive correc-
tion for multiple testing. No evidence of an association be-
tween CNVs of 100 kb or greater and 1 Mb or greater and de-
pression was found (Table).
Exploratory analysis of individual neurodevelopmental
CNVs found 8 CNVs to be nominally associated with self-
reported depression, of which 3 (1q21.1 duplication, Prader-
Willi syndrome duplication, and 16p11.2 duplication) sur-
vived Bonferroni correction for the 53 neurodevelopmental
CNVs tested (Pvalue thresholdof .00094;Figure2andeTable 1
in the Supplement).
Association Between CNVs and Depression Severity
We used data from the 157 397 individuals who completed
an online follow-up mental health questionnaire to examine
the association between CNVs and markers of depression
severity (age at onset, number of depressive episodes, and
duration of worst depressive episode). We restricted these
analyses to the 68684 affected individuals who reported ex-
periencingprolonged feelingsof sadnessordepression (57243
unaffected), a phenotype that itself was associatedwith neu-
rodevelopmental CNV carrier status (OR, 1.20; 95% CI, 1.07-
1.36; P = .002).We did not find any association between neu-
rodevelopmentalCNVsandmarkersofdepressionseverity that
survivedcorrection formultiple testing (eTable2 in theSupple-
ment). Themental healthquestionnaire providespotential al-
ternativedepressionvariables.Among thesevariablesareade-
pression phenotype constructed using the Composite
InternationalDiagnostic Interview—ShortForm,as reportedby
Davis et al,39 and an alternative self-reporteddepressionvari-
able.We examined these depression phenotypes for their as-
sociation with neurodevelopmental CNVs and found consis-
tent results when compared with the primary depression
definitions, although the effect sizeswere somewhat smaller,
as would be expected for milder depression definitions
(eTable 10 in the Supplement).
Further Investigation of the Neurodevelopmental CNV
and Depression Association
Tobetter understand the association betweenneurodevelop-
mental CNVs anddepression,we investigatedwhether the as-
sociationcouldbeexplainedbymeasuresof (1) educational at-
tainment (qualifications), (2) physical health (presence or
absence of an associated medical phenotype), (3) social de-
privation (Townsend deprivation index), (4) smoking (smok-
ing status), and (5) alcohol consumption (alcohol intake fre-
quency). These variableswere chosenbecauseof their known
associations with depression,31-34 their postulated or proven
associationwithCNVs, and their availability in a largepropor-
tion of theUKBiobank sample. The association betweenneu-
rodevelopmental CNVs and depression was partially ex-
plained by each variable examined: 1.2% explained by
educational attainment; 2.9%, physical health; 8.1%, social
deprivation; 4.8%, smoking status; and 16.6%, alcohol con-
sumption (Figure 3 and eTable 3 in the Supplement). A strong
independent association remained between the neurodevel-
opmental CNVs and depression in analyses that incorporated
Figure 2. Analyses of Individual Neurodevelopmental Copy Number
Variants (CNVs) for AssociationWith Self-reported Depression
Odds Ratio
129630
TAR del
TAR dup
1q21.1 del
1q21.1 dupa
NRXN1 delb
2q11.2 del
2q13 del
2q13 dup
3q29 delb
8p23.1 dupb
15q11.2 del
PWS dupa
15q13.3 del
15q24 dup
16p13.11 delb
16p13.11 dup
16p12.1 del
16p11.2 distal del
16p11.2 distal dup
16p11.2 del
16p11.2 dupa
Potocki Lupski syndrome del
17q11.2 del
17q12 dup
22q11.2 del
22q11.2 dupb
Neurodevelopmental CNVs
Schizophrenia CNVs
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Del indicates deletion; dup, duplication.
a CNVs that survived Bonferroni correction for 53 tests.
b Results with P < .05. Schizophrenia CNVs are shown as light blue. All CNVs fall
within the neurodevelopmental CNV group. The dashed line indicates an odds
ratio of 1.
Figure 3. Association Between Neurodevelopmental Copy Number
Variants (CNVs) and Depression
Direct effect estimate: 0.018
Indirect effect estimates:
 Physical health 0.00053
 Smoking status 0.00088
 Alcohol consumption 0.0031
 Educational attainment 0.00023
 Social deprivation 0.0015
Neurodevelopmental
CNVs Depression
The numbers shown are estimates for direct and indirect effects of each of the
5 variables (educational attainment, physical health, social deprivation, smoking
status, and alcohol consumption), calculated using structural equationmodeling
in the lavaanpackage in R (R Foundation for Statistical Computing).36 Full results,
including SEs and P values, are shown in eTable 3 in the Supplement.
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these other measures (OR, 1.26; 95% CI, 1.11-1.43;
P = 2.87 × 10−4).
Sex-Specific Analyses
Given the recent evidence of an increased rate of large CNVs
in female children with anxiety or depression,38 we under-
took an exploratory analysis, which provided weak evidence
of a higher rate of depression among female carriers of neu-
rodevelopmental CNV than among male carriers. This in-
creased rate was over and above the baseline-increased rate
of self-reported depression in females (interaction term
OR, 0.66; 95%CI, 0.53-0.83; uncorrected P = .002; eTables 4
and 5 in the Supplement). However, this association was
weaker for the secondary depression definitions.
Discussion
To our knowledge, this research is the largest study of CNVs
in depression to date. We performed a CNV analysis of
depression in the UK Biobank sample of 407074 individuals
with European genetic ancestry. The primary definition of
depression was an individual’s self-report of ever having
received a medical diagnosis of depression (self-reported
depression). To ensure that the findings were not restricted
to this definition, we also tested 2 more conservative pheno-
types: (1) lifetime self-reported depression with current anti-
depressant prescription at the time of visit 1 and (2) hospital
discharge diagnosis of depression. We sought association
with depression for a group of 53 CNVs known to be associ-
ated with neurodevelopmental disorders,3 and after exclud-
ing individuals with CNVs relevant to the primary hypoth-
esis, we tested for a residual explained burden among CNVs
of 100 kb or greater, 500 kb or greater, and 1 Mb or greater.
The results support our first hypothesis that CNVs that were
previously associated with neurodevelopmental disorders
are associated with increased risk of lifetime depression,
whether defined on the basis of self-reported diagnosis, self-
reported diagnosis combined with antidepressant treatment,
or on hospital discharge diagnosis. This analysis excluded
those with a neurodevelopmental or neuropsychiatric diag-
nosis, and thus the association is unlikely to have been
explained by associations with these disorders.
Three neurodevelopmental CNVs (1q21.1 duplication,
Prader-Willi syndrome duplication, and 16p11.2 duplication)
were individually associated with depression at levels of sta-
tistical significance, survivingBonferroni correction for the53
neurodevelopmentalCNVstested.Noneof theseCNVlociover-
lap with risk loci recently identified in a large depression ge-
nome-wide association study.18 The risk of depression inCNV
carriers in the current study (whether CNVs were considered
individually or collectively)was lower comparedwith the risk
identified inpreviousstudiesof schizophrenia.However,quali-
tatively, the results followeda similar pattern:Thehighest risk
for both disorders was conferred by 3q29del (depression
OR, 11.22 vs schizophrenia OR, 57.65) and the lowest risk for
bothdisorderswasconferredby16p12.1del (depressionOR, 1.47
vs schizophrenia OR, 3.3).5,6 After excluding neurodevelop-
mental CNVs,we foundnoevidence of residual burdenof risk
for depression among CNVs of 100 kb or greater, 500 kb or
greater, and 1 Mb or greater.
Further investigationof theassociationbetweenneurode-
velopmental CNVs and depression risk indicated that this as-
sociation is partially explainedbyeducational attainment, so-
cial deprivation, physical health, smoking status, and alcohol
consumption.Toourknowledge, this is the first study to show
theseCNVsare associatedwithneighborhoodmeasures of so-
cial deprivation, and thus it implicates an important mecha-
nismbywhichCNVcarrier status could increase the riskofde-
pression. Longitudinal data on thesemeasures are needed to
establish the causal directionality between depression and
social deprivation.
Limitations
This studyhas some limitations. Theprimarydepressiondefi-
nition relied on self-report, a method known to be subject to
informationbias.40However, thisdefinition isunlikely tohave
markedly affected the findings, given the almost identical, or
even stronger, results from using the clinicians’ hospital dis-
charge diagnosis of depression phenotype. Another limita-
tion is the relatively low rate of depression comparedwith the
population estimates.41 This lower rate may have been asso-
ciatedwith thebetter-than-averagehealth and functioningof
the UK Biobank sample and the imprecise definition of de-
pression. However, these factors were not likely to have gen-
erated spurious CNV associations andwould instead have di-
luted the associations with CNV carrier status.
Conclusions
Neurodevelopmental CNVs have incomplete penetrance for
major developmental disorders,42 yet beyond their associa-
tionwithmild cognitive impairment,26,43 little is knownabout
their phenotypic associations with CNV carrier status. This
study, to our knowledge, is the first to robustly demonstrate
theassociationbetween theseCNVsand riskofdepressionand
thus extends the spectrumof clinical phenotypes that are as-
sociatedwithCNVcarrier status. Thiswork reiterates that car-
riers of CNVs without neurodevelopmental disorders cannot
be assumed to be unimpaired. It appears that alongwith cog-
nitive and physical health manifestations, wider implica-
tions for depression and social deprivation must be consid-
ered in assessing CNVs at the population level.
ARTICLE INFORMATION
Accepted for Publication: January 3, 2019.
Published Online: April 17, 2019.
doi:10.1001/jamapsychiatry.2019.0566
Open Access: This is an open access article
distributed under the terms of the CC-BY License.
© 2019 Kendall KM et al. JAMA Psychiatry.
Author Contributions:Drs Kendall andWalters had
full access to all of the data in the study and take
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: Kendall, O'Donovan, Owen,
Jones, Kirov, Walters.
Acquisition, analysis, or interpretation of data:
Research Original Investigation Association of Rare Copy Number Variants With Depression
E6 JAMAPsychiatry Published online April 17, 2019 (Reprinted) jamapsychiatry.com
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 04/18/2019
Kendall, Rees, Bracher-Smith, Legge, Riglin,
Zammit, O'Donovan, Jones, Kirov, Walters.
Drafting of the manuscript: Kendall, O'Donovan,
Walters.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Kendall, Rees, Bracher-Smith,
Legge, Kirov, Walters.
Obtained funding: Kendall, Owen, Jones, Walters.
Administrative, technical, or material support:
O'Donovan.
Supervision:O'Donovan, Owen, Jones, Kirov,
Walters.
Conflict of Interest Disclosures:Dr Kendall
reported receiving grants fromWellcome Trust and
grants from theMedical Research Council (MRC)
during the conduct of the study. Dr Bracher-Smith
reported receiving grants from theMRC during the
conduct of the study. Drs O'Donovan, Owen, and
Walters reported receiving grants from theMRC
during the conduct of the study and grant MR/
P005748/1 for molecular genetic studies of
schizophrenia; and reported receiving grants from
Takeda Pharmaceuticals outside of the submitted
work. No other disclosures were reported.
Funding/Support: This study was funded in part
by aWellcome Trust Clinical Research Training
Fellowship award (Dr Kendall). The work at Cardiff
University was supported byMRC Centre grant
MR/L010305/1, Program grant G0800509, and
Project grant MR/L011794/1.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
REFERENCES
1. Cooper GM, Coe BP, Girirajan S, et al. A copy
number variationmorbidity map of developmental
delay. Nat Genet. 2011;43(9):838-846. doi:10.1038/
ng.909
2. Williams NM, Franke B, Mick E, et al.
Genome-wide analysis of copy number variants in
attention deficit hyperactivity disorder: the role of
rare variants and duplications at 15q13.3. Am J
Psychiatry. 2012;169(2):195-204. doi:10.1176/appi.
ajp.2011.11060822
3. Coe BP, Witherspoon K, Rosenfeld JA, et al.
Refining analyses of copy number variation
identifies specific genes associated with
developmental delay. Nat Genet. 2014;46(10):
1063-1071. doi:10.1038/ng.3092
4. Girirajan S, Brkanac Z, Coe BP, et al. Relative
burden of large CNVs on a range of
neurodevelopmental phenotypes. PLoS Genet.
2011;7(11):e1002334. doi:10.1371/journal.pgen.
1002334
5. Rees E, Walters JT, Georgieva L, et al. Analysis of
copy number variations at 15 schizophrenia-
associated loci. Br J Psychiatry. 2014;204(2):108-114.
doi:10.1192/bjp.bp.113.131052
6. Rees E, Kendall K, Pardiñas AF, et al. Analysis of
intellectual disability copy number variants for
association with schizophrenia. JAMA Psychiatry.
2016;73(9):963-969. doi:10.1001/jamapsychiatry.
2016.1831
7. International Schizophrenia Consortium. Rare
chromosomal deletions and duplications increase
risk of schizophrenia.Nature. 2008;455(7210):237-
241. doi:10.1038/nature07239
8. Stefansson H, Rujescu D, Cichon S, et al; GROUP.
Large recurrent microdeletions associated with
schizophrenia. Nature. 2008;455(7210):232-236.
doi:10.1038/nature07229
9. Glessner JT, Wang K, Sleiman PM, et al.
Duplication of the SLIT3 locus on 5q35.1
predisposes tomajor depressive disorder. PLoS One.
2010;5(12):e15463. doi:10.1371/journal.pone.
0015463
10. Degenhardt F, Priebe L, Herms S, et al.
Association between copy number variants in
16p11.2 andmajor depressive disorder in a German
case-control sample. Am JMed Genet B
Neuropsychiatr Genet. 2012;159B(3):263-273.
doi:10.1002/ajmg.b.32034
11. O’Dushlaine C, Ripke S, Ruderfer DM, et al. Rare
copy number variation in treatment-resistant major
depressive disorder. Biol Psychiatry. 2014;76(7):
536-541. doi:10.1016/j.biopsych.2013.10.028
12. Rucker JJ, Breen G, Pinto D, et al. Genome-wide
association analysis of copy number variation in
recurrent depressive disorder.Mol Psychiatry. 2013;
18(2):183-189. doi:10.1038/mp.2011.144
13. Rucker JJ, Tansey KE, Rivera M, et al.
Phenotypic association analyses with copy number
variation in recurrent depressive disorder. Biol
Psychiatry. 2016;79(4):329-336. doi:10.1016/j.
biopsych.2015.02.025
14. Perlis RH, Ruderfer D, Hamilton SP, Ernst C.
Copy number variation in subjects with major
depressive disorder who attempted suicide. PLoS
One. 2012;7(9):e46315. doi:10.1371/journal.pone.
0046315
15. Tansey KE, Rucker JJ, Kavanagh DH, et al. Copy
number variants and therapeutic response to
antidepressant medication in major depressive
disorder. Pharmacogenomics J. 2014;14(4):395-399.
doi:10.1038/tpj.2013.51
16. Rees E, Walters JT, Chambert KD, et al;
Wellcome Trust Case Control Consortium. CNV
analysis in a large schizophrenia sample implicates
deletions at 16p12.1 and SLC1A1 and duplications at
1p36.33 and CGNL1. Hum Mol Genet. 2014;23(6):
1669-1676. doi:10.1093/hmg/ddt540
17. Cross-Disorder Group of the Psychiatric
Genomics Consortium. Identification of risk loci
with shared effects on five major psychiatric
disorders: a genome-wide analysis. Lancet. 2013;
381(9875):1371-1379. doi:10.1016/S0140-6736(12)
62129-1
18. Wray NR, Ripke S, MattheisenM, et al;
eQTLGen; 23andMe; Major Depressive Disorder
Working Group of the Psychiatric Genomics
Consortium. Genome-wide association analyses
identify 44 risk variants and refine the genetic
architecture of major depression.Nat Genet. 2018;
50(5):668-681. doi:10.1038/s41588-018-0090-3
19. Cooper SA, McLean G, Guthrie B, et al. Multiple
physical andmental health comorbidity in adults
with intellectual disabilities: population-based
cross-sectional analysis. BMC FamPract. 2015;16:110.
doi:10.1186/s12875-015-0329-3
20. Buckley PF, Miller BJ, Lehrer DS, Castle DJ.
Psychiatric comorbidities and schizophrenia.
Schizophr Bull. 2009;35(2):383-402. doi:10.1093/
schbul/sbn135
21. Smith DJ, Nicholl BI, Cullen B, et al. Prevalence
and characteristics of probable major depression
and bipolar disorder within UK biobank:
cross-sectional study of 172,751 participants. PLoS
One. 2013;8(11):e75362. doi:10.1371/journal.pone.
0075362
22. Howard DM, AdamsMJ, Shirali M, et al;
23andMe Research Team. Genome-wide
association study of depression phenotypes in UK
Biobank identifies variants in excitatory synaptic
pathways. Nat Commun. 2018;9(1):1470. doi:10.
1038/s41467-018-03819-3
23. Spijker J, de Graaf R, Bijl RV, Beekman AT,
Ormel J, NolenWA. Duration of major depressive
episodes in the general population: results from the
Netherlands Mental Health Survey and Incidence
Study (NEMESIS). Br J Psychiatry. 2002;181(3):208-
213. doi:10.1192/bjp.181.3.208
24. Murphy S. Genotyping of 500,000UK Biobank
participants. Description of sample workflow and
preparation of DNA for genotyping.
https://biobank.ctsu.ox.ac.uk/crystal/docs/
genotyping_sample_workflow.pdf. Published April
27, 2015. Accessed July 7, 2017.
25. Wang K, Li M, Hadley D, et al. PennCNV:
an integrated hiddenMarkovmodel designed for
high-resolution copy number variation detection in
whole-genome SNP genotyping data. Genome Res.
2007;17(11):1665-1674. doi:10.1101/gr.6861907
26. Kendall KM, Rees E, Escott-Price V, et al.
Cognitive performance among carriers of
pathogenic copy number variants: analysis of
152,000 UK Biobank subjects. Biol Psychiatry. 2017;
82(2):103-110. doi:10.1016/j.biopsych.2016.08.014
27. Crawford K, Bracher-Smith M, Owen D, et al.
Medical consequences of pathogenic CNVs in
adults: analysis of the UK Biobank. J Med Genet.
2019;56(3):131-138. doi:10.1136/jmedgenet-2018-
105477
28. Purcell S, Neale B, Todd-Brown K, et al. PLINK:
a tool set for whole-genome association and
population-based linkage analyses. Am J HumGenet.
2007;81(3):559-575. doi:10.1086/519795
29. Maechler M, Rousseeuw P, Croux C, et al.
robustbase: basic Robust Statistics R package
version 0.93-2. R Package. http://cran.r-project.org/
package=robustbase. Accessed December 12, 2018.
30. Hubert M, Rousseeuw PJ, Verdonck T. A
deterministic algorithm for robust location and
scatter. J Comput Graph Stat. 2012;21(3):618-637.
doi:10.1080/10618600.2012.672100
31. Lorant V, Deliège D, EatonW, Robert A,
Philippot P, AnsseauM. Socioeconomic inequalities
in depression: a meta-analysis. Am J Epidemiol.
2003;157(2):98-112. https://www.ncbi.nlm.nih.gov/
pubmed/12522017. doi:10.1093/aje/kwf182
32. Egede LE. Major depression in individuals with
chronic medical disorders: prevalence, correlates
and association with health resource utilization, lost
productivity and functional disability. Gen Hosp
Psychiatry. 2007;29(5):409-416. doi:10.1016/j.
genhosppsych.2007.06.002
33. Fluharty M, Taylor AE, Grabski M, Munafò MR.
The association of cigarette smoking with
depression and anxiety: a systematic review.
Nicotine Tob Res. 2017;19(1):3-13. doi:10.1093/ntr/
ntw140
Association of Rare Copy Number Variants With Depression Original Investigation Research
jamapsychiatry.com (Reprinted) JAMAPsychiatry Published online April 17, 2019 E7
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 04/18/2019
34. Boden JM, Fergusson DM. Alcohol and
depression. Addiction. 2011;106(5):906-914.
doi:10.1111/j.1360-0443.2010.03351.x
35. Davies G, Marioni RE, Liewald DC, et al.
Genome-wide association study of cognitive
functions and educational attainment in UK
Biobank (N=112 151).Mol Psychiatry. 2016;21(6):
758-767. doi:10.1038/mp.2016.45
36. Rosseel Y. lavaan: an R package for structural
equationmodeling. J Stat Softw. 2012;48(2):1-36.
doi:10.18637/jss.v048.i02
37. Han J, Walters JT, Kirov G, et al. Gender
differences in CNV burden do not confound
schizophrenia CNV associations. Sci Rep. 2016;6:
25986. doi:10.1038/srep25986
38. Martin J, Tammimies K, Karlsson R, et al. Copy
number variation and neuropsychiatric problems in
females andmales in the general population.
[published online October 11. Am JMed Genet B
Neuropsychiatr Genet. 2018. doi:10.1002/ajmg.b.
32685
39. Davis KAS, Coleman JRI, AdamsM, et al.
Mental health in UK Biobank: development,
implementation and results from an online
questionnaire completed by 157 366 participants.
BJPsych Open. 2018;4(3):83-90. doi:10.1192/bjo.
2018.12
40. Althubaiti A. Information bias in health
research: definition, pitfalls, and adjustment
methods. J Multidiscip Healthc. 2016;9:211-217.
doi:10.2147/JMDH.S104807
41. Maier W, Gänsicke M, Gater R, Rezaki M,
Tiemens B, Urzúa RF. Gender differences in the
prevalence of depression: a survey in primary care.
J Affect Disord. 1999;53(3):241-252. doi:10.1016/
S0165-0327(98)00131-1
42. Kirov G, Rees E, Walters JT, et al.
The penetrance of copy number variations for
schizophrenia and developmental delay. Biol
Psychiatry. 2014;75(5):378-385. doi:10.1016/j.
biopsych.2013.07.022
43. Stefansson H, Meyer-Lindenberg A,
Steinberg S, et al. CNVs conferring risk of autism or
schizophrenia affect cognition in controls.Nature.
2014;505(7483):361-366. doi:10.1038/nature12818
Research Original Investigation Association of Rare Copy Number Variants With Depression
E8 JAMAPsychiatry Published online April 17, 2019 (Reprinted) jamapsychiatry.com
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 04/18/2019
